ESRRG Knockout HEK293 Cell Line
Cat.No.:
EDJ-KQ4557
Species:
Human
Cell Name:
HEK293
Gene:
ESRRG
Gene ID:
2104
Size:
1×10⁶cells
ESRRG Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDJ-KQ4557 |
|---|---|
| Product Name | ESRRG Knockout Cell Line (HEK293) |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene | |
| NCBI Gene ID | |
| Gene Synonyms | ERR-gamma|ERR3|ERRg|ERRgamma|NR3B3 |
| Summary |
This gene encodes a member of the estrogen receptor-related receptor (ESRR) family, which belongs to the nuclear hormone receptor superfamily. All members of the ESRR family share an almost identical DNA binding domain, which is composed of two C4-type zinc finger motifs. The ESRR members are orphan nuclear receptors; they bind to the estrogen response element and steroidogenic factor 1 response element, and activate genes controlled by both response elements in the absence of any ligands. The ESRR family is closely related to the estrogen receptor (ER) family. They share target genes, co-regulators and promoters, and by targeting the same set of genes, the ESRRs seem to interfere with the ER-mediated estrogen response in various ways. It has been reported that the family member encoded by this gene functions as a transcriptional activator of DNA cytosine-5-methyltransferases 1 (Dnmt1) expression by direct binding to its response elements in the DNMT1 promoters, modulates cell proliferation and estrogen signaling in breast cancer, and negatively regulates bone morphogenetic protein 2-induced osteoblast differentiation and bone formation. Multiple alternatively spliced transcript variants have been identified, which mainly differ at the 5' end and some of which encode protein isoforms differing in the N-terminal region. [provided by RefSeq, Aug 2011]
|
| Associated Diseases | Non-tumor |
| Morphology | Adherent |
| Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Research Publications
Genetic variants in ESRRG are associated with a dominant non-progressive congenital movement disorder with ataxia.
IF=8.1
American journal of human genetics
The orphan nuclear hormone receptor estrogen-related receptor γ (ESRRG, also known as ERRγ) functions as an inducible transcription factor, regulating the expression of endocrine and metabolic genes. Among its ESRR paralogs, ESRRG exhibits the highest mutational constraint, yet it remains unlinked to a defined disease phenotype. We clinically describe eight individuals from seven unrelated families having heterozygous, mostly de novo variants in ESRRG: c.410G>A (p.Gly137Glu), c.446A>G (p.Lys149Arg), c.539G>A (p.Cys180Tyr), c.550C>T (p.Arg184Cys), c.1346T>G (p.Leu449Arg), and c.1352dup (p.Leu451Phefs38). Cell proliferation and ERR response element (ERRE) reporter gene expression have been examined in transient transfected ESRRG-knockout HEK293T cells for each variant compared to wild-type ESRRG. Immunofluorescence was performed to inspect the protein's subcellular localization. All identified variants are absent in gnomAD (v.4.1), are in silico deleterious, and are located in intolerant segments of the protein. All individuals have motor developmental delay, muscular hypotonia, and eye movement disorders, as well as congenital ataxia or gait imbalance. Other symptoms include joint hyperflexibility, dysarthria, myopia, and growth delay. Molecular modeling of the identified variants suggests a reduction in protein function. ESRRG knockout resulted in a significantly increased proliferation rate in ESRRG-knockout HEK293T cells. Overexpression of wild-type ESRRG restored cell proliferation, while overexpression of the identified variants did not. Despite the correct nuclear localization of all identified variants, the reporter gene assay revealed a significant reduction in transcriptional activity for all identified variants. Given the acquired clinical, molecular, and functional data, we implicate ESRRG in the etiology of a non-progressive congenital movement disorder with ataxia.
This KO model may be useful for:
- Investigating the molecular basis of non-progressive congenital movement disorder with ataxia
- Functional validation of heterozygous missense and frameshift ESRRG variants (e.g., p.Gly137Glu, p.Lys149Arg, p.Cys180Tyr, p.Arg184Cys, p.Leu449Arg, p.Leu451Phefs38)
- Assessing transcriptional activity at ERR response elements (ERRE) in reporter gene assays
- Studying the role of ESRRG in regulating cell proliferation rates
- Analyzing subcellular localization and nuclear trafficking of mutant ESRRG proteins